Meeting
2024 ASCO Annual Meeting
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).
Presenter
Benjamin Avi Derman, MD
University of Chicago
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Clinical Science Symposium
Session Title
Use of MRD-Guided Strategies to Optimize Therapeutic Interventions
Track
Special Sessions,Gastrointestinal Cancer—Colorectal and Anal,Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary,Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT04108624
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 106)
DOI
10.1200/JCO.2024.42.16_suppl.106
Abstract #
106
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Final results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple myeloma (MM).
Speaker: Sheeba K. Thomas, MD
Videos & Slides
2023 ASCO Annual Meeting
Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): A phase 2 study with a safety run-in.
Speaker: Ajay K. Nooka, MBBS
Videos & Slides
2022 ASCO Annual Meeting
The Role of Measurable Residual Disease Testing in Myeloma in the Quest for Cure
Speaker: Ajay K. Nooka, MBBS
Videos & Slides
2021 ASCO Annual Meeting
Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.
Speaker: Robert M. Rifkin, MD, FACP